Skip to main content
. 2020 Sep 23;137(3):323–335. doi: 10.1182/blood.2020006770

Figure 1.

Figure 1.

Toxicity and efficacy after CART2. (A) CRS grade according to the Lee et al 2014 consensus criteria (left).28 Neurotoxicity grade according to the CTCAE 4.03 grading scale (right). (B) Response rates by disease type. CTCAE, Common Terminology Criteria for Adverse Events; SD, stable disease.